Although the emergence of a PARP inhibitor, Olaparib, currently used as a maintenance treatment for ovarian cancer, represented a major breakthrough in cancer treatment, resistance has emerged [4, 5].PARP inhibitors initially show good clinical response, but most patients develop resistance to these drugs [6–8]. Here, PARP1 is linked to ovarian cancer.